BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27400681)

  • 1. GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer.
    Gu J; Wang D; Zhang J; Zhu Y; Li Y; Chen H; Shi M; Wang X; Shen B; Deng X; Zhan Q; Wei G; Peng C
    Cancer Lett; 2016 Oct; 380(2):434-441. PubMed ID: 27400681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer.
    Ni S; Wang H; Zhu X; Wan C; Xu J; Lu C; Xiao L; He J; Jiang C; Wang W; He Z
    Oncotarget; 2017 Jan; 8(5):8010-8021. PubMed ID: 28030829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer.
    Bao B; Ali S; Kong D; Sarkar SH; Wang Z; Banerjee S; Aboukameel A; Padhye S; Philip PA; Sarkar FH
    PLoS One; 2011 Mar; 6(3):e17850. PubMed ID: 21408027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.
    Fan P; Liu L; Yin Y; Zhao Z; Zhang Y; Amponsah PS; Xiao X; Bauer N; Abukiwan A; Nwaeburu CC; Gladkich J; Gao C; Schemmer P; Gross W; Herr I
    Cancer Lett; 2016 Apr; 373(1):130-137. PubMed ID: 26828016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
    Ju HQ; Zhuang ZN; Li H; Tian T; Lu YX; Fan XQ; Zhou HJ; Mo HY; Sheng H; Chiao PJ; Xu RH
    Cancer Lett; 2016 Aug; 379(1):1-11. PubMed ID: 27233476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARID3A enhances chemoresistance of pancreatic cancer via inhibiting PTEN-induced ferroptosis.
    Mao X; Xu J; Xiao M; Liang C; Hua J; Liu J; Wang W; Yu X; Meng Q; Shi S
    Redox Biol; 2024 Jul; 73():103200. PubMed ID: 38781729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
    Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y
    Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
    Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
    Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miRNA-93-5p Promotes Gemcitabine Resistance in Pancreatic Cancer Cells by Targeting the PTEN-Mediated PI3K/Akt Signaling Pathway.
    Wu Y; Xu W; Yang Y; Zhang Z
    Ann Clin Lab Sci; 2021 May; 51(3):310-320. PubMed ID: 34162560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Xiong G; Huang H; Feng M; Yang G; Zheng S; You L; Zheng L; Hu Y; Zhang T; Zhao Y
    J Exp Clin Cancer Res; 2018 Apr; 37(1):76. PubMed ID: 29615098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
    Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW
    Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
    Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y
    Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A decrease in miR-150 regulates the malignancy of pancreatic cancer by targeting c-Myb and MUC4.
    Yang K; He M; Cai Z; Ni C; Deng J; Ta N; Xu J; Zheng J
    Pancreas; 2015 Apr; 44(3):370-9. PubMed ID: 25522282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
    Giovannetti E; Funel N; Peters GJ; Del Chiaro M; Erozenci LA; Vasile E; Leon LG; Pollina LE; Groen A; Falcone A; Danesi R; Campani D; Verheul HM; Boggi U
    Cancer Res; 2010 Jun; 70(11):4528-38. PubMed ID: 20460539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
    Xu BQ; Fu ZG; Meng Y; Wu XQ; Wu B; Xu L; Jiang JL; Li L; Chen ZN
    Oncotarget; 2016 Sep; 7(38):62177-62193. PubMed ID: 27556697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression.
    Duan W; Chen K; Jiang Z; Chen X; Sun L; Li J; Lei J; Xu Q; Ma J; Li X; Han L; Wang Z; Wu Z; Wang F; Wu E; Ma Q; Ma Z
    Cancer Lett; 2017 Jan; 385():225-233. PubMed ID: 27773749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing of long noncoding RNA LINC00958 prevents tumor initiation of pancreatic cancer by acting as a sponge of microRNA-330-5p to down-regulate PAX8.
    Chen S; Chen JZ; Zhang JQ; Chen HX; Qiu FN; Yan ML; Tian YF; Peng CH; Shen BY; Chen YL; Wang YD
    Cancer Lett; 2019 Apr; 446():49-61. PubMed ID: 30639194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity.
    Sharbeen G; Youkhana J; Mawson A; McCarroll J; Nunez A; Biankin A; Johns A; Goldstein D; Phillips P
    Oncotarget; 2017 Feb; 8(6):9216-9229. PubMed ID: 27999205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.